While people with cancer have options to participate in cancer clinical trials (CCTs), it can be challenging when they encounter difficulties enrolling and remaining in the trial. Trial withdrawal, although every participant’s right, can thwart study goals and hamper advancing novel treatments.
The COVID-19 pandemic brought many troubling ethical issues to the frontlines of clinical care, creating significant distress for clinicians, patients, and families. Behind the scenes, clinical ethicists managed those issues to support front-line workers and were integral to hospital operations.
Cancer clinical trials (CCTs) provide patients an opportunity to receive experimental drugs, tests, and/or procedures that can lead to remissions. For some, a CCT may seem like their only option. Yet little is known about the experiences of patient participants who withdraw from CCTs.